JP2020533969A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533969A5
JP2020533969A5 JP2020511428A JP2020511428A JP2020533969A5 JP 2020533969 A5 JP2020533969 A5 JP 2020533969A5 JP 2020511428 A JP2020511428 A JP 2020511428A JP 2020511428 A JP2020511428 A JP 2020511428A JP 2020533969 A5 JP2020533969 A5 JP 2020533969A5
Authority
JP
Japan
Prior art keywords
vector
foxp3
cell
lentiviral
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020511428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533969A (ja
JP7290288B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/047586 external-priority patent/WO2019040655A1/en
Publication of JP2020533969A publication Critical patent/JP2020533969A/ja
Publication of JP2020533969A5 publication Critical patent/JP2020533969A5/ja
Application granted granted Critical
Publication of JP7290288B2 publication Critical patent/JP7290288B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020511428A 2017-08-22 2018-08-22 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でfoxp3を発現するレンチウイルスベクター Active JP7290288B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548891P 2017-08-22 2017-08-22
US62/548,891 2017-08-22
PCT/US2018/047586 WO2019040655A1 (en) 2017-08-22 2018-08-22 LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES

Publications (3)

Publication Number Publication Date
JP2020533969A JP2020533969A (ja) 2020-11-26
JP2020533969A5 true JP2020533969A5 (cg-RX-API-DMAC7.html) 2021-09-30
JP7290288B2 JP7290288B2 (ja) 2023-06-13

Family

ID=65439627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020511428A Active JP7290288B2 (ja) 2017-08-22 2018-08-22 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でfoxp3を発現するレンチウイルスベクター

Country Status (5)

Country Link
US (2) US12060566B2 (cg-RX-API-DMAC7.html)
EP (1) EP3672617A4 (cg-RX-API-DMAC7.html)
JP (1) JP7290288B2 (cg-RX-API-DMAC7.html)
KR (1) KR102780121B1 (cg-RX-API-DMAC7.html)
WO (1) WO2019040655A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3532105B1 (en) 2016-10-31 2025-07-09 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogennous foxp3 gene
WO2019040655A1 (en) 2017-08-22 2019-02-28 The Regents Of The University Of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES
US11713459B2 (en) 2018-04-27 2023-08-01 Seattle Children's Hospital Expression of FOXP3 in edited CD34+ cells
WO2019210078A1 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of human foxp3 in gene edited t cells
US20220168394A1 (en) * 2019-04-23 2022-06-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing or restoring immune tolerance
WO2020247805A1 (en) * 2019-06-07 2020-12-10 The Board Of Trustees Of The Leland Stanford Junior University Foxp3 engineered cd4+ t cells for use in treg-based immunotherapy
WO2021028359A1 (en) * 2019-08-09 2021-02-18 Sangamo Therapeutics France Controlled expression of chimeric antigen receptors in t cells
US20240400993A1 (en) * 2021-09-27 2024-12-05 Kyoto University Method for producing t cell
CN119256076A (zh) * 2022-03-23 2025-01-03 国立大学法人京都大学 用于产生调节性t细胞的方法
AU2023353929A1 (en) * 2022-09-26 2025-05-01 Kyoto University T cell production method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090600A2 (en) 2001-05-08 2002-11-14 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
JP2004208548A (ja) 2002-12-27 2004-07-29 Institute Of Physical & Chemical Research 免疫反応の抗原特異的抑制
WO2008141282A2 (en) * 2007-05-11 2008-11-20 The Regents Of The University Of Michigan Materials and methods for foxp3 tumor suppression
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
WO2014121840A1 (en) * 2013-02-07 2014-08-14 Medizinische Hochschule Hannover Induced dendritic cells and uses thereof
GB201318347D0 (en) * 2013-10-16 2013-11-27 Ucl Business Plc Retroviral vectors
KR102796744B1 (ko) * 2015-06-09 2025-04-15 에디타스 메디신, 인코포레이티드 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물
WO2019040655A1 (en) 2017-08-22 2019-02-28 The Regents Of The University Of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES

Similar Documents

Publication Publication Date Title
JP2020533969A5 (cg-RX-API-DMAC7.html)
Merten et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application
Wolff et al. Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 years
Nienhuis Development of gene therapy for blood disorders: an update
RU2014117201A (ru) ЛЕНТИВИРУСНЫЕ ВЕКТОРЫ, ПСЕВДОТИПИРОВАННЫЕ МУТАНТНЫМИ BaEV
JP7290288B2 (ja) 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でfoxp3を発現するレンチウイルスベクター
Galimi et al. Opportunities for the use of lentiviral vectors in human gene therapy
JP2020010684A5 (cg-RX-API-DMAC7.html)
IL320371A (en) Gene therapy for patients with fanconi anemia
WO2009013324A9 (en) Vector particles for targeting cd34+ cells
WO2016039933A1 (en) Lentiviral vector for treating hemoglobin disorders
Lundstrom Gene therapy applications of viral vectors
JP2023544633A (ja) 治療における使用のためのrag1の置き換え
Bell Jr et al. RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors
Cesani et al. Shedding of clinical-grade lentiviral vectors is not detected in a gene therapy setting
Curran et al. Nonprimate lentiviral vectors
Bergmann et al. Progress and problems with viral vectors for delivery of talens
Miyake et al. Selective killing of human immunodeficiency virus-infected cells by targeted gene transfer and inducible gene expression using a recombinant human immunodeficiency virus vector
CN116635523A (zh) 用于疗法中的rag1的替代物
Salmon et al. Lentiviral vectors for the gene therapy of lympho-hematological disorders
Dalberto et al. Mesenchymal stem cells as a platform for gene therapy protocols
Shunchang et al. Expression of truncated dystrophin cDNAs mediated by a lentiviral vector
Counsell et al. 527. Exploiting Retroviral Recombination for the Delivery of Full-Length Dystrophin cDNA
JP2024538769A (ja) Rag1遺伝子における突然変異を修正するのに有用なポリヌクレオチド
US20230040417A1 (en) Defective interfering particles